Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Cinclus Pharma Holding AB (publ)
AB
Active
Org 5591368765
Kungsbron 1, 111 22
Stockholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2017 · 8 years old
19 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Cinclus Pharma Holding AB (publ)
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
78M
59M
39M
20M
0M
2021: 10M
10M
2021
2022: 8M (-20% vs 2021)
8M
-20%
2022
2023: 1M (-87% vs 2022)
1M
-87%
2023
2024: 1M (0% vs 2023)
1M
0%
2024
2025: 63M (+6200% vs 2024)
63M
+6200%
2025
EBITDA
SEK millions
0M
-64M
-128M
-191M
-255M
2021: -11M
-11M
2021
2022: -181M (-1545% vs 2021)
-181M
-1545%
2022
2023: -205M (-13% vs 2022)
-205M
-13%
2023
2024: -173M (+16% vs 2023)
-173M
+16%
2024
2025: -199M (-15% vs 2024)
-199M
-15%
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
62 894
1 376
628
8 431
10 410
Staff expenses
—
—
—
—
—
EBITDA
−198 604
−172 975
−204 754
−180 890
−11 292
Depreciation & amort.
—
—
—
—
—
EBIT
−198 604
−172 975
−204 754
−180 890
−11 292
Net financials
68 460
−1 318
−28 744
−38 629
6 764
Profit before tax
−117 029
−170 000
−217 757
−198 930
−4 529
Tax
−0
−0
−0
−0
−0
Net profit
−117 029
−170 000
−217 757
−198 930
−4 529
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
842 818
1 000 695
497 722
578 607
360 941
Equity
681 859
795 718
168 221
383 701
355 441
Long-term debt
35 587
0
0
0
0
Short-term debt
125 373
204 977
329 501
194 906
5 501
Total debt
160 960
204 977
329 501
194 906
5 501
Financial ratios
5-year trend
EBITDA margin
−315,8 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2021
2025
Equity ratio
80,9 %
This company
38,2 %
Market median
This company
Market median
112% above market
2021
2025
Return on equity
−17,2 %
This company
18,4 %
Market median
This company
Market median
193% below market
2021
2025
Net profit margin
−186,1 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2021
2025
Asset turnover
0,07×
This company
1,12×
Market median
This company
Market median
94% below market
2021
2025
Debt / equity
0,24×
This company
0,62×
Market median
This company
Market median
61% below market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
More on Cinclus Pharma Holding AB (publ)
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
